Key facts
- This page summarizes Weiss Lawrence T.'s Form 4 filing for ANGIODYNAMICS INC (ANGO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Dec 2024, 21:33.
Weiss Lawrence T. - 02 Dec 2024 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)
- Reporting relationship
- SVP, Chief Legal Officer
- Issuer ticker
- ANGO
- Reported as of
- 02 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Dec 2024, 21:33:45 UTC
- Prior SEC filing
- 06 Jul 2023
- Next SEC filing
- 18 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lawrence Weiss
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Weiss Lawrence T. filed Form 4 for ANGIODYNAMICS INC (ANGO) on 04 Dec 2024.
Change
- Previous filing in this sequence was filed on 06 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANGO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +52,697
- Change %
- Price
- $0.000000
- Shares after
- 52,697
- Date
- 02 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANGO
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +103,650
- Change %
- Price
- $0.000000
- Shares after
- 103,650
- Date
- 02 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 103,650
- Exercise price
- $7.14
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The acquisition of 52,697 shares of common stock ("Common Stock") of AngioDynamics, Inc.("AngioDynamics") represents 52,697 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on December 2, 2025, such that 25% of the restricted stock units will vest on each of December 2, 2025, 2026, 2027 and 2028.
Footnote F2
These stock options vest in four equal annual installments beginning on December 2, 2025, such that 25% of the options will vest on each of December 2, 2025, 2026, 2027 and 2028.